Subscribe To

Price Alert Latest News Economic Calendar News

DAWN / Diving Into Day One Biopharmaceuticals

Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis' combination therapy received first approval for pLGG. However, its lead candidate (tovorafenib) has the potential to treat all BRAF-mutated pLGG patients, whereas Novartis' combo only addresses about 10% to 20% of that population. With tovorafenib's somewhat risky rolling NDA submission slated for October 2023 and ample cash for commercialization, the recent beneficial owner buying merited a look into this busted IPO. Read More

Demo Live Account See Partner Details

Content Topics

Diving

Into

Biopharmaceuticals

Stock

DAWN

Posted: Jul 23 2023, 04:43

Author Name: Seeking Alpha

DAWN News

By Seeking Alpha
July 23, 2023

Diving Into Day One Biopharmaceuticals

Shares of precision oncology concern Day One Biopharmaceuticals, Inc. are down over 50% from their 2023 high as Novartis' combination therapy received

By The Motley Fool
June 5, 2023

Why Shares of Day One Pharmaceuticals Are Up Monday

Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The company s

By Market Watch
June 5, 2023

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Day One Biopharmaceuticals DAWN, -0.37% shares climbed 23% in premarket trading Monday after the company shared new data on tovorafenib, an investigat

By Proactive Investors
May 1, 2023

Day One Biopharmaceuticals stock rallies as 1Q results show the brain tumor treatment candidate producer is funded into 2025

Day One Biopharmaceuticals stock added more than 16% Monday afternoon after the company posted its first-quarter financial results. The Brisbane, Ca

By Seeking Alpha
April 7, 2023

Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns

Day One Biopharmaceuticals is looking to file an NDA after successful glioma data. DAWN is well-financed, having been VC supported in the initial year

By GlobeNewsWire
December 20, 2022

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company d

By Seeking Alpha
September 4, 2022

Day One Biopharmaceuticals: Recent Strong Data, And Major Catalysts Ahead

Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash position.

By InvestorPlace
June 13, 2022

Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today?

Today's announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. The post Why Is Da

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.